Kornimate/medical-research-clean huggingface dataset:
a clinical trial to evaluate the time point of anti-vegf pretreatment of pdr based on intraoperative ffa

Conditions: The Condition of Fundus Neovascularization

Summary: the goal of this prospective randomized controlled study is to compare the therapeutic effect of injecting anti-vegf drugs before surgery for patients with proliferative diabetic retinopathy at different time points. at present, studies have confirmed that anti-vegf drugs are effective in inhibiting fundus neovascularization in proliferative diabetic retinopathy. the main question it aims to answer is which time point is better to injecting anti-vegf drugs before surgery for patients with proliferative diabetic retinopathy. participants will be randomly divided into three groups. and time points of injecting anti-vegf drugs before surgery for each group will be 3 days, 7 days, 14 days. and we have a new technology that can have fluorescein fundus angiography during operation, so it can reflect the condition of fundus neovascularization immediately and precisely. in that case, we can compare the inhibitory effect of anti-vegf drugs on fundus neovascularization at different time points.


Eligibility criteria:
inclusion criteria: * pdr is diagnosed in people 18 years of age or older with type 1 or type 2 diabetes， * hemoglobin a1c (hba1c) ≤10% * persistent vitreous hemorrhage for more than one month or recurrent vitreous hemorrhage (within six months) * did not undergo retintis photocoagulation (prp) * vitreous hemorrhage disease course within six months exclusion criteria: * patients who have had previous vitreoretinal surgery * intravitreal drug injection within 3 months * eye diseases other than pdr that may hinder vision improvement, such as optic atrophy or macular hole * thromboembolic events (including cerebrovascular or myocardial infarction) or clotting system disorders or receiving anticoagulation or antiplatelet therapy * b-ultrasound or indirect fundus microscopy showing retina detachment (pull or hole origin) * vitrectomy, ffa contraindicated patients, patients with severe abnormality of cardiopulmonary, liver and kidney function
the impact of procedural awareness of knee injections for osteoarthritis on patient perceptions of effectiveness

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to determine whether outcomes for patients receiving intra-articular platelet-rich plasma (prp) injections for knee osteoarthritis are influenced by observation of the preparatory steps to the procedure. the viewing of the steps involved in the administration of prp may increase the effectiveness of the treatment in comparison to patients who have not observed the preparatory steps.


Eligibility criteria:
inclusion criteria: * adult men or women ages 50-80 years * diagnosis of symptomatic osteoarthritis of the knee based on clinical and radiographic criteria * provision of informed consent exclusion criteria: * patients with inflammatory osteoarthritis * open wounds or sores over the knee joint * patients that will likely have problems, in the judgement of the investigators, with maintaining follow-up
investigating the neural signature of freezing of gait in parkinson's disease

Conditions: Parkinson Disease; Freezing of Gait; Basal Ganglia Diseases; Brain Disease; Movement Disorders; Neurodegenerative Disease

Summary: freezing of gait (fog) is a disabling symptom of parkinson's disease (pd) and a leading cause for falls. current medical management is inadequate to alleviate fog so there is need for improved treatments. a major draw-back in the development of better treatments for fog is the difficulty in detecting episodes and our poor understanding of its underlying pathophysiology. this study will investigate the cortical signature of fog using ambulatory electroencephalography (eeg) to help improve fog detection algorithms and provide novel insights into the underlying pathophysiology, which together will guide therapy development.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of parkinson's disease (pd) made by a neurologist\* 2. modified hoehn \& yahr (h\&y) stage i to iv in the on medication state 3. age above 18 years\* 4. able to walk 5 minutes while unassisted by a walker or another person (the use of a cane is allowed).\* 5. mini mental state examination\>= 21 6. at least three hours in-between regular medication intakes to allow for stable testing time.\* 7. self-reported fog with a severity of at least 1 fog episode per day, based on items 1 and 2 of the new freezing of gait questionnaire, irrespective of fog occurring on- or off-medication.\* 8. stable medication scheme for at least 7 days before enrollment. exclusion criteria: 1. participation in another clinical intervention study\* 2. acute musculoskeletal or other neurological, psychiatric, or cardiovascular conditions affecting gait or any other medical condition which, in the opinion of the investigator, may prevent the participant from completing the protocol in full 3. unable to adhere to assessment procedures leading to missing or unusable data, as determined by the investigators 4. not a stable medication scheme for at least 7 days before the assessment.\* 5. occurrence of any of the following within 3 months prior to informed consent: * orthopedic surgery of the lower extremity * myocardial infarction * hospitalization for unstable angina * coronary artery bypass graft * percutaneous coronary intervention * implantation of a cardiac resynchronization therapy device * implantation of deep brain stimulation 6. substance abuse that may interfere with the patient's compliance

Keywords: parkinson&#39;s disease electroencephalography (eeg) freezing of gait gait problems
graft take and microbiology in burns

Conditions: Transplantation Infection; Wound of Skin; Burns; Graft Loss; Infection

Summary: split-thickness skin graft take and microbiological evaluation in burned patients introduction: infection is cause of increased morbidity and mortality in burn patients, and its control is a major challenge also for skin graft integration. wound and soft tissue infection rates are higher than microbiological diagnosis rates. purpose: to evaluate partial skin graft integration in relation to microbiological analysis of wounds in burn patients. methods: this project will be a transversal, prospective, analytical, controlled study in humans, conducted in a single center, at burn care unit of department of plastic surgery at federal university of são paulo from october, 2010 to october, 2011. data will be collected to characterize demographic and clinical aspects. data analysis will be performed using student's t-test and friedman analysis of variance.

split-thickness skin graft take and microbiological evaluation in burned patients introduction: early excision and partial skin graft is state-of-the-art in burns treatment. otherwise, infection is cause of increased morbidity and mortality in burn patients, and its control is a major challenge also for skin graft integration. wound and soft tissue infection rates are higher than microbiological diagnosis rates. this difference is related to moderate sensibility of cultures in general. precise bacterial diagnostic and its susceptibility to specific antibiotics are prerequisite for adequate treatment of burn patients and skin graft integration. purpose: to evaluate partial skin graft integration in relation to microbiological analysis of wounds in burn patients. methods: this project was approved at ethics committee at federal university of são paulo (1272/10). it will be a transversal, prospective, analytical, controlled study in humans, conducted in a single center, at burn care unit of department of plastic surgery at federal university of são paulo from october, 2010 to october, 2011. thirty patients will be included in this study after reading and signing a consent form. data will be collected using an evaluation sheet to characterize demographic and clinical aspects, including partial skin graft integration, use of topical and systemic antibiotics and infection rates in all sites (blood, urine, skin, tracheal aspirate and bronchial lavage). data analysis will be performed using student's t-test and friedman analysis of variance.

Eligibility criteria:
inclusion criteria: * both gender * more than 18 years of age * burned patient * inpatient of burn center of federal university of são paulo * upper 5% of tbsa * debridement and skin graft indication and procedure realization exclusion criteria: * not interest in participating in research * not have debridement or graft indication * under 5% of tbsa * skin disease * clinical disease that contraindication procedure * clinical disease that directly interferes with infectious process and wound healing

Keywords: transplantation infection wound of skin burns graft loss infection
fecal microbiota transplantation for the treatment of obesity

Conditions: Obesity

Summary: this is a randomized controlled pilot study to assess the microbiological and clinical impacts of fecal microbiota transplantation (fmt) in patients with obesity. the investigators will prospectively enroll 20 adult patients who are obese (body mass index of 35kg/m2 or higher) after providing written informed consent. the study participants will be randomized 1:1 to either the treatment arm or the placebo arm. the treatment arm will receive an induction fmt with capsules followed by a monthly maintenance dose of oral capsules for 12 weeks total. the placebo group will receive a placebo capsules for induction followed by monthly intake of oral placebo capsules for 12 weeks.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. obesity defined as a bmi of 35kg/m2 or higher exclusion criteria: 1. triglycerides \> 500 mg/dl 2. use of antibiotics \<8 weeks prior to participation 3. use of probiotics \<4 weeks prior to participation 4. alcohol use of greater than 20g/daily or suspicion of alcohol abuse and dependence 5. substance abuse, current 6. lfts greater then 3x the uln 7. cirrhosis. 8. dm type 2 that is insulin dependent, treated with glp1-agonists, or poorly controlled on oral medications (hba1c \> 10%) 9. use of any weight loss medication or participation in a weight loss study or program such as weight watchers 10. history of recent weight change (weight loss or weight gain in the two months preceding trial enrollment). this is defined as a gain or loss of 10 or more pounds in the preceding 2 months 11. patients who are pregnant or breastfeeding 12. patients who are unable to give informed consent 14. patients who have previously undergone fmt 15. patients who have a confirmed malignancy or cancer 16. patients who are immunocompromised 17. participation in a clinical trial in the preceding 30 days or simultaneously during this trial 18. previous gastric or small intestinal surgery that alters gut anatomy such as fundoplication, gastric resection, gastric bypass, small bowel resection, and ileocectomy 19. other comorbidities including: systemic lupus, inflammatory bowel disease, or chronic kidney disease as defined by a gfr \<60ml/min/1.73m2 44 20. history of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia 21. any condition, based on clinical judgment that may make study participation unsafe 22. history of severe food allergies 23. use of immune modulators including methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, thalidomide, interleukin-10, or interleukin-11 24.treatment with infliximab, adalimumab, certolizumab, natalizumab, vedolizumab or thalidomide 25. congenital or acquired immunodeficiencies

Keywords: obesity fmt
perception and representation of internal body in anorexia nervosa

Conditions: Anorexia Nervosa

Summary: this study focuses on representations of the interior of the body and interoceptive awareness in women with anorexia nervosa in comparison with women without eating disorders.


Eligibility criteria:
inclusion criteria: * anorexia nervosa according to dsm-5 * aged above than 14 * bmi between 14 and 18.5 for adults or less than the reference age by age for minors exclusion criteria: * unable to understand the tests, poor understanding of the french language * mental retardation * severe psychiatric comorbidity (bipolar disorder, schizophrenia) * lesion or pathology of the upper limbs * pregnancy * absence of social protection * hospitalization under duress

Keywords: body awareness interoceptive awareness anorexia nervosa adolescent body image
communication by brain - computer interface in amyotrophic lateral sclerosis:feasibility study

Conditions: Amyotrophic Lateral Sclerosis

Summary: als is a severe progressive neurodegenerative disease characterized by degeneration motor neurons leading to death in 3 to 5 years. gradually in time, the patient deprived of all motor skills as well as the possibility of communication written and oral developing a state close locked in syndrome (lis). the main objective is to establish the feasibility of brain-computer interface using the pathological condition, with dependent disabled subjects as a means of communication.


Eligibility criteria:
inclusion criteria: * age \>= 18 * have a diagnosis of als suspected, possible, probable with emg * be able to follow the study process and to comply with the schedule of visits upon entry into the study * understand the purpose of the study * expressing p300 wave in the conditions of the study exclusion criteria: * have a mental illness or clinical dementia defined clinically significant may hinder the patient's ability to follow the procedures of the study * have a significant history of photosensitive epilepsy * have a history of allergy to the gel used for the electrodes * major protected by law (guardianship, curators) * have uncorrectable visual disorders * not being able to maintain a sitting position and focus on a computer screen for more than 30 min.
preoperative vaginal dinoprostone versus misoprostone in abdominal myomectomy

Conditions: Myoma;Uterus

Summary: aim and objectives; to compare the efficacy of preoperative administration of dinoprostone 20 mg versus 400 ug misoprostol vaginally in decreasing the amount of bleeding during abdominal myomectomy

background; myomectomy is a curative interventional option for many kinds of uterine fibroids, but considerable intraoperative haemorrhage and the necessities for transfusions of blood are still the main challenge for abdomen myomectomy. aim and objectives; to compare the efficacy of preoperative administration of dinoprostone 20 mg versus 400 ug misoprostol vaginally in decreasing the amount of bleeding during abdominal myomectomy subjects and methods; this was a prospective randomized double-blind controlled study that included 90 patients complaining of uterine myoma and indicated for myomectomy selected from the outpatient clinic at beni-suef university hospital

Eligibility criteria:
inclusion criteria: * age 30-50 years * all cases with uterine fibroid not responding to medical treatment and indicated for myomectomy. exclusion criteria: * contraindications to dinoprostone or misoprostol, * active pid, * history of pelvic/ ovarian endometriosis, * females who had pre-operative mifepristone, gnrh analog or orally contraception drugs, earlier myomectomy.

Keywords: uterine leiomyoma misoprostol dinoprostone
efficacy and safety of viusid in patients with nonalcoholic steatohepatitis

Conditions: Nonalcoholic Steatohepatitis

Summary: the purpose of the study is to evaluate whether viusid, a nutritional supplement, in combination with diet and exercise improve the histological results (steatosis, necro-inflammatory activity and fibrosis) in comparison with diet and exercise, during 24 weeks of treatment.


Eligibility criteria:
inclusion criteria: * histological diagnosis of steatohepatitis (minimal histological criteria for steatohepatitis include steatosis involving at least 5% of hepatocytes, lobular inflammation, and/or fibrosis) * age between 18 and 70 years * ability to provide informed consent * absence of significant alcohol ingestion (weekly ethanol consumption of less than 40 g) exclusion criteria: * presence of other form of liver diseases (viral or autoimmune hepatitis, drug-induced liver disease, metabolic and hereditary liver disease and α-1 antitrypsin deficiency) * pregnancy or lactation * decompensated cirrhosis * presence of secondary cause of nafl such as medications that induce steatosis (corticosteroids, estrogens, methotrexate, amiodarone, tamoxifen and calcium channel blockers) and gastrointestinal bypass surgery * pharmacological treatment with some potential benefit on nafl including ursodeoxycholic acid, vitamin e, betaine, pioglitazone, rosiglitazone, metformin, pentoxifylline or gemfibrozil * fasting glucose levels greater than 250 mg per deciliter (13.3 mmol per liter) * contraindication to liver biopsy * refusal to participate in the study * concomitant disease with reduced life expectancy * severe psychiatric conditions * drug dependence

Keywords: nonalcoholic steatohepatitis nonalcoholic fatty liver nutritional supplement diet exercise
a trial for patients with gestational trophoblastic disease

Conditions: Trophoblastic Neoplasms; Uterine Neoplasms; Hydatidiform Mole; Choriocarcinoma

Summary: this phase ii study is evaluating the activity of pemetrexed in patients diagnosed with low risk gestational trophoblastic tumor (gtt) that have failed prior treatment.


Eligibility criteria:
inclusion criteria: * persistent or recurrent low risk gestational trophoblastic tumor (gtt) * who score 2-6 (re-evaluated at the time of relapse * histologically confirmed complete or partial moles on initial evacuation * patients with mild to moderate renal insufficiency should avoid taking nsaids with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of pemetrexed. * all patients taking nsaids with longer half-lives, should interrupt dosing for at least 5 days before, the day of, and 2 days following pemetrexed administration. * folic acid (350-1000 micrograms) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. * vitamin b12 (1000 micrograms) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. exclusion criteria: * previous treatment that included chemotherapy other than actinomycin -d or methotrexate (+/- folinic acid). * patients with more than 8 metastatic lesions identified * patients with metastases to liver, spleen, brain, kidney or gi tract
sublingual vs intrauterine misoprostol plus oxytocin infusion for prevention of post-cesarean hemorrhage in high risk pregnant women: a double-blind placebo rct

Conditions: To Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk Women

Summary: research objective: primary outcome -to compare efficacy intrauterine vs sublingual misoprostol in addition to oxytocin in reducing blood loss of post-cesarean section in high risk women secondary outcome -to study hemoglobin/hematocrit change, need of uterotonic agents, need of blood transfusion, adverse drug event of intrauterine vs sublingual misoprostol plus oxytocin compare to oxytocin alone hypothesis: -intrauterine misoprostol plus oxytocin is not inferior to sublingual misoprostol plus oxytocin in reducing blood loss of post-cesarean section in high risk women

research design: double-blind randomized placebo controlled trial subject: singleton pregnancy ga 34 wk or more with high risk for postpartum hemorrhage undergo cesarean section with spinal anesthesia in rajavithi hospital allocated to 3 groups * group1: misoprostol sublingually 2 tab (400 mcg) + oxytocin 20 iu intravenous + placebo intrauterine 2 tab * group2: misoprostol intrauterine 2 tab (400 mcg) + oxytocin 20 iu intravenous + placebo sublingually 2 tab * group3: oxytocin 20 iu intravenous + placebo intrauterine 2 tab + placebo sublingually 2 tab

Eligibility criteria:
inclusion criteria: * ≥35 ปี * previous pph * morbid obesity * fetal macrosomia * polyhydramnios * induction/augmentation of labour * prolonged labour * grand multiparity * preeclampsia * myoma uteri exclusion criteria: * asthma * maternal fever/ tripple i can't excluded * coagulopathy * placenta previa/ adherens/ abruptio placenta * allergy to prostaglandins/oxytocin

Keywords: postpartum hemorrhage, cesarean section, sublingual misoprostol, intrauterine misoprostol
open-label extension study of evolocumab (amg 145) in adults with hyperlipidemia and mixed dyslipidemia

Conditions: Hyperlipidemia and Mixed Dyslipidemia

Summary: this study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (amg 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.


Eligibility criteria:
inclusion criteria: - complete a qualifying evolocumab (amg 145) parent study (ie, study 20110114 \[nct01763827\], 20110115 \[nct01763866\], 20110116 \[nct01763905\], 20110117 \[nct01763918\], 20110109 \[nct01516879\], 20120122 \[nct01953328\], 20120332 \[nct01984424\], 20120348 \[nct01849497\], or 20120356 \[nct01879319\]). exclusion criteria: * experienced a treatment-related serious adverse event that led to study drug discontinuation in the parent study * have an unstable medical condition, in the judgment of the investigator * known sensitivity to any of the products to be administered during dosing * currently enrolled in another investigational device or drug study (excluding evolocumab (amg 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)

Keywords: high cholesterol raised cholesterol cholesterol elevated cholesterol